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An assay for determining the concentration of pyridoxal Y-phosphate in plasma from 
0.4 ml whole blood is reported. The assay consists of incubating deproteinized 
plasma with o-setine apodehydratase from Escherichia cob’ in 0.5 M N-2-hydroxyethyl- 
pipetazine-N’-3-propesulfonic acid, pH 7.8, at 37°C for 15 mitt, and then determining 
the o-serine dehydratase activity of an aliquot of the incubation mixture. A lactic 
dehydrogenase-coupled assay (at 25°C) was used to measure the rate of enzymicahy 
catalyzed conversion of D-serine to pyruvate, wherein depletion of NADH was followed 
continuously at 340 nm. The concentration of pyridoxal Y-phosphate in the plasma 
samule was estimated from the enzymic activity which is a linear function of the amount of 
pyridoxal 5’-phosphate present in the assay. 
Inadequate vitamin Bs nut~tion in labo- 
ratory animals and humans may cause 
serious abnormalities such as arteriosclerotic 
lesions (I), convulsions (2,3), sideroblastic 
anemia (4), neuropathy (5), and deficient 
cerebral myelination during early develop- 
ment (6). It is important to note that without 
dietary supplementation, the levels of 
vitamin Bs in certain population groups 
may fall below that which is required 
to maintain a healthy state. Pregnant women 
(7,8), alcoholics (9,10), and women taking 
oral contraceptives (I 1) are among the 
population groups which appear to have low 
levels of vitamin Bg. Patients undergoing 
therapy with certain drugs such as isoniazid 
(5) and penicillamine (12), which react with 
pyridoxal Y-phosphate (pyridoxal-P),3 have 
I Present address: Department of Chemistry, Uni- 
versity of California, Berkeley, Calif. 
* To whom inquiries regarding this work should be 
addressed. 
3 Abbreviations used: AP, a solution containing 
a depro~inized plasma sample which has been ad- 
justed to pH 7.8; ape-DSD, u-serine a~hyd~~se; 
AU, absorbance unit; BSA, bovine serum albumin; 
been reported to suffer from abnormalities 
associated with vitamin B, deficiency, 
which are reversed when their diet is sup- 
plemented with pyridoxine. 
The availability of convenient and re- 
liable methods for determining vitamin Bs 
nutrition would facilitate studies of the 
molecular basis for abnormalities char- 
acteristic of inadequate vitamin Bs nutrition. 
Such assays also would aid in diagnosis 
of the need for dietary supplementation 
with pyridoxine prior to the onset of 
clinical symptoms and irreversible damage. 
Plasma levels of pyridoxal-P have been 
shown to be a reliable measure of vitamin 
Bs nutrition in laboratory animals and 
humans (13- 17). Up to now, however, the 
most reliable and convenient assay for the 
concentration of pyridoxal-P in plasma has 
been based upon the extent of reconstitu- 
DSD, n-serine dehydratase; DTT, dithiothreitol; 
Hepps, N-Z-hydroxyethyIpi~~zine-N’-3-propanesul- 
fonic acid; LDH, lactic dehydrogenase; PMSF, 
phenylmeth~esulfony~~uo~de; pyridoxal-P, pyridoxat 
S-phosphate. 
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tion of the activity of tyrosine apode- 
carboxylase (9,18-20). Unfortunately, the 
tyrosine decarboxylase assays are dis- 
continuous assays which require measure- 
ment of radiochemically labeled CO, re- 
leased in the enzymically catalyzed reaction. 
In this work, we report a simpler con- 
tinuous spectrophotometric assay for plasma 
levels of pyridoxal-P which involves re- 
constitution of D-serine apodehydratase 
(apo-DSD), by the pyridoxal-P present in a 
sample, and determination of the activity of 
the reconstituted enzyme formed from the 
rate of enzymically catalyzed conversion 
of D-serine to pyruvate in an LDH- 
coupled assay. 
METHODS 
Materials. Dithiothreitol (DTT), L-cyste- 
ine, ribonuclease (bovine pancreas, A 
grade), deoxyribonuclease (bovine pan- 
creas, B grade), and bovine serum albumin 
(BSA, crystallized A grade) were obtained 
from Calbiochem. Phenylmethanesulfonyl- 
fluoride (PMSF) was from Eastman. N-2- 
Hydroxyethylpiperazine - N’ - 3 - propane- 
sulfonic acid (Hepps), D-serine, and lactic 
dehydrogenase (LDH, type I: crude) were 
from Sigma. The Hepps buffers used in this 
work were prepared by partial neutraliza- 
tion of solutions of Hepps with KOH so 
that the indicated pH values and total 
final concentrations of buffer were obtained. 
NaOH should not be substituted for KOH 
in the preparation of these buffers, since 
sodium ion inhibits reconstitution of the 
enzyme. Prior to use the LDH was dialyzed 
against 300 vol of 0.1 M Hepps buffer, pH 
7.5, for 24 h with one change of buffer. 
BSA was acetylated according to the pro- 
cedure of Epstein and Goldberger (21). 
Ammonium sulfate (ultrapure, enzyme 
grade) was from Schwarz/Mann. All other 
chemicals used were reagent grade. The 
distilled water supplied to the laboratory 
was passed through a Barnstead deionizer 
and redistilled in an all-glass Corning 
AG-2 still. 
Protein concentrations and units of D- 
serine dehydratase (DSD) at 25°C were 
determined as described previously (22). 
DSD was isolated from the C6 mutant 
of Escherichia coli (ATCC 25842) by a 
procedure similar to that of Dowhan and 
Snell (23). A more easily obtainable, crude 
form of DSD was also found to be adequate 
for use in determinations of pyridoxal-P 
and its preparation will be described here. 
C6 E. coli K12 cells were reisolated and 
grown as reported previously (22). Deoxy- 
ribonuclease and ribonuclease (1 mg each 
per 1 liter of suspension) were added to 1 
kg of cell paste which had been suspended 
in an equal volume of 0.01 M potassium 
phosphate buffer, pH 7.2. The suspension 
was then cooled to 4°C and the cells were 
disrupted by two passages through a Gaulin 
homogenizer at 900 psi. The 43,OOOg 
(1 h) supernatant solution from the cell 
homogenate was adjusted to pH 6 with 
10 N KOH and cooled to 13°C. Nucleic 
acids were precipitated by addition (over 
20 min with stirring) of 2 ml of 2% aqueous 
protamine sulfate (at pH 5.0) per milligram 
of supernatant protein. After another 5 min 
of stirring, the solution was cooled rapidly 
to 4°C and the precipitate removed by 
centrifugation at 15,OOOg for 1 h. Protein 
was precipitated from the solution at 4°C 
by the addition (with stirring over 1 h) of 
saturated ammonium sulfate (4°C) to 56.6% 
saturation. After another 30 min of stirring 
at 4”C, the precipitated protein was 
removed by centrifugation (15,000g for 70 
min) and dissolved in a minimum volume 
of 0.01 M potassium phosphate, pH 7.2. The 
pH of the resulting solution was adjusted 
to pH 7.0 with 1 M K,HPO, and the solu- 
tion diluted with 0.01 M potassium phos- 
phate, pH 7.2, to a protein concentration 
of 40 mg/ml. An equal volume of acetone 
at -70°C (dry ice-ethanol) was added to 
the diluted solution over a period of 7- 10 
min with stirring. Stirring was continued for 
5 min at -10°C (ice-ethanol) and the 
precipitate was removed by centrifugation 
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in polypropylene tubes at 30,OOOg for 10 
min. Acetone was removed from the 
supernatant solution at 20°C by rapid 
evaporation on a Buchi rotary evaporator 
with the condensing coil cooled with cir- 
culating ethylene glycol at -5°C and the 
receiving flask in an ethanol-ice bath at 
-10°C. In order to minimize the time 
required to evaporate the acetone, no more 
than 250 ml of protein solution was treated 
with acetone at one time. 
The suspension remaining after evapora- 
tion of the acetone was centrifuged for 20 
min at 39,000g and the supernatant solu- 
tion adjusted to 60 units/ml. After cooling 
this solution to 4”C, protein was pre- 
cipitated by addition (with stirring over 15- 
20 min) of sufficient saturated ammonium 
sulfate (4°C) so that the final solution was 
at 56.5% staturation. The precipitated pro- 
tein was removed by centrifugation at 
15,000g for 50 min and used as crude 
DSD. The yield was 660 mg of protein 
with a specific activity of 20-40 units/mg. 
Pure DSD was obtained from crude DSD 
by the following procedure. Crude DSD was 
dissolved in a minimum volume of 0.01 M 
potassium phosphate buffer, pH 7.8, and 
exhaustively dialyzed against 0.01 M po- 
tassium phosphate buffer which contained 
0.01 M 2-mercaptoethanol and 1 pM pyri- 
doxal-P. If necessary the dialyzed solution 
was clarified by centrifugation for 20 min 
at 4O,OOOg, and subjected to DEAE- 
cellulose chromatography according to step 
8 of the procedure of Dowhan and Snell 
(23). The fractions highest in DSD activity 
were combined and concentrated to 1000 
units/ml by ultrafiltration. The resulting 
solution was diluted to 675 units/ml with a 
buffer such that the final solution was 
0.1 M phosphate, 1 mM DTT, and 5 pM 
pyridoxal-P, pH 7.8. Saturated ammonium 
sulfate was added dropwise with stirring 
to the enzyme solution at room tempera- 
ture so that the final saturation (4°C con- 
ditions) was 27%. If no signs of turbidity 
were evident, the ammonium sulfate was 
added to a maximum of 30% saturation. 
The resulting solution was allowed to stand 
in the dark at 4°C until crystallization was 
complete. One recrystallization is usually 
required to bring the specific activity up to 
that of pure enzyme (150-160 units/mg). 
Recrystallized enzyme (85 mg) was stored 
at 4°C in the dark under 0.1 M potassium 
phosphate buffer, pH 7.0-7.2, which con- 
tained 1 mM DTT, 10 pM pyridoxal-P, 
and ammonium sulfate at 50% saturation. 
Resolution of crude and pure DSD was 
performed using a procedure similar to that 
of Dowhan and Snell (23). Typically, 
enzyme at lo-20 mg protein/ml in 0.1 M 
potassium phosphate buffer, pH 7.8, was 
dialyzed against 100 vol of resolving buffer. 
Sufficient resolving buffer for resolution 
was prepared by adding prior to initiation 
of the resolution procedure solid cysteine 
(to 0.5 M) and DTT (to 1 mM) to a solution 
consisting of 0.4 M imidazole and 10 mM 
EDTA which had been adjusted to pH 6.5 
by the addition of solid citric acid. The pH 
of the resulting solution was then re- 
adjusted to 6.5 by the addition of con- 
centrated KOH, and was deaerated by 
bubbling nitrogen through the solution for 
30 min with stirring. The deaerated solution 
was stored in a stoppered bottle under 
argon until used in dialysis. Just prior to 
use in dialysis, each portion of resolving 
buffer was made 0.1 mM PMSF by addition 
of 85 mM PMSF in ethanol. This procedure, 
which presumably inactivated serine prote- 
ases, markedly increased the yield and 
stability of apoenzyme from crude DSD. 
Dialysis was carried out in a cylinder fitted 
with a two-hole stopper to allow entrance 
and exit of nitrogen which was bubbled 
through the resolving buffer during dialysis. 
Care was taken to ensure that the dialysate 
was well stirred and that the dialysis sac 
rotated freely. The resolving buffer was 
changed every 6 h until the desired degree 
of resolution was obtained, as measured by 
comparing the residual activity of the 
enzyme to that generated after incubating 
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the enzyme with 1 PM pyridoxal-P. 
Between 20 and 30 h of dialysis was usually 
required to obtain enzyme which had an 
activity less than 0.1% that of fully re- 
constituted enzyme. Resolved enzyme was 
separated from the resolving buffer by gel 
filtration on a column of Sephadex G-25 
(coarse) which was eluted with 0.1 M po- 
tassium phosphate, 1 mM DTT, pH 7.8. 
After elution from the Sephadex column 
a sevenfold excess by weight of acetylated 
BSA was added to the pure apo-DSD. No 
acetylated BSA was added to the crude 
apo-DSD. In both cases the protein solution 
was diluted with distilled water about 
sevenfold and lyophilized. 
Withdrawal and treatment of blood. 
Blood4 was withdrawn from normal volun- 
teers by venipuncture after an overnight 
fast, and collected in a syringe or vacutainer 
containing sufficient 200 mM EDTA diso- 
dium salt to yield a final EDTA concen- 
tration of 2 mM in the sample. The plasma 
was separated from the whole blood by 
centrifugation and deproteinized by vig- 
orously mixing 1 vol of 3 N HClO, with 9 
vol of plasma on a Vortex mixer. After 10 
min at room temperature, the precipitated 
protein was removed by centrifugation. An 
aliquot (~0.10 ml) of deproteinized plasma 
was then mixed with an equal volume of a 
solution consisting of 0.1 M Hepps, 50 mM 
EDTA which had been adjusted to pH 8.75 
with 10 N KOH. The resulting solution was 
incubated in an ice bath for 45 min 
and the precipitated KClO, removed by 
centrifugation. The supernatant solution 
(AP), which was at pH 7.8, was stored in 
the dark. 
Assays for pyridoxal-P involved a two- 
step procedure wherein apoenzyme was re- 
constituted by a sample containing pyri- 
doxal-P and then assayed. Approximately 
4 Determination of the plasma concentration of 
pyridoxal-P from a single enzymic assay can be ac- 
complished with a 0.4-ml sample of blood. 
2.5 mg of lyophilizate5 from pure apo-DSD 
or 6.5 mg lyophilizate5 from crude apo-DSD 
was dissolved in 1 ml of a buffer consisting 
of 0.5 M Hepps, 50 mM EDTA, 5 mM 
DTT, 1 mM PMSF, 10% ethanol, at pH 7.8. 
Insoluble material was removed by cen- 
trifugation and, when necessary, the result- 
ing solution was diluted with additional 
buffer in order to adjust the AzBO of the 
solution to 0.20 when pure apo-DSD was 
used and to 0.42 when crude apo-DSD was 
used.6 To reconstitute the apoenzyme, 100 
~1 of a sample containing pyridoxal-P in 
AP or in 0.5 M Hepps, pH 7.8, was mixed 
with 50 ,ul of the solution of apoenzyme 
and 25 ~1 of 0.5 M Hepps, pH 7.8, which 
in some cases contained a known amount of 
added pyridoxal-P as a calibration stand- 
ard. After 15 min at 37°C ‘100 ~1 of the 
reconstitution mixture was removed and 
added to 1 ml of 0.5 M Hepps, pH 7.8, in a 
cuvette at 25°C. The assay was initiated after 
15 min at 25°C by the addition of 50 ~1 
of a solution consisting of 5 mM NADH, 
0.22 M o-serine, 350 units LDH activity/ml, 
in 0.5 M Hepps, pH 7.8. The decrease in 
absorbance at 340 nm was followed on a 
recording spectrophotometer for at least 
0.1 absorbance unit, and the slope equated 
to the activity of the enzyme. Standard 
solutions containing known amounts of 
pyridoxal-P for calibration of the assay were 
prepared by dilution of a stock solution of 
pyridoxal-P in 0.1 M sodium phosphate, pH 
5 The lyophilizate consists mainly of salts and is 
less than 10% protein. 
6 These absorbance values correspond to apo- 
enzyme concentrations of 0.6 PM as determined by 
titration with pyridoxal-P. The possible presence of 
oxidized DTT in samples of apo-DSD made it im- 
practical to calculate the operational normality of 
the apoenzyme solution from its absorbance. A solution 
of apo-DSD will respond well in the assays for plasma 
pyridoxal-P if the observed enzymic activity increases 
by lo- to 20-fold when the concentration of pyridoxal-P 
is increased from 15 nM (limiting pyridoxal-P) to 
1 PM (excess pyridoxal-P) in the reconstitution 
mixture. 
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7.0, wherein the molar absorptivity of 
pyridoxal-P is 4900 M-l cm-’ at 388 nm (24). 
RESULTS AND DISCUSSION 
The assays for pyridoxal-P that are 
described in this work consist of incubating 
samples containing pyridoxal-P with excess 
apo-DSD in 0.5 M Hepps, pH 7.8, at 37°C 
for 15 min, and then transferring an aliquot 
of the incubation mixture to a cuvette for 
determination of its DSD activity. DSD- 
catalyzed conversion of D-set-me to pyruvate 
was monitored using an LDH-coupled assay 
similar to that described by Dowhan and 
Snell(23), wherein depletion of NADH upon 
its reaction with pyruvate in the LDH- 
catalyzed reaction was followed in a con- 
tinuous spectrophotometric assay at 340 nm. 
In these assays, the decrease in absorbance 
was linearly dependent on time for about 
0.9 absorbance unit, and the rate of change 
of absorbance was not altered by increasing 
the concentration of LDH. 
Figure 1 shows the linear dependence of 
enzymic activity on the amount of pyri- 
doxal-P in the assay cuvette with freshly 
prepared pure apo-DSD and with crude 
apo-DSD after several months of storage as 
a lyophilized powder at 4°C. Since apo- 
DSD combines with pyridoxal-P with a 1:l 
stoichiometry to form active enzyme (25,26), 
a comparison of the activity generated 
per mole of added pyridoxal-P7 with the 
specific activity of pure holoenzyme under 
the assay conditions should indicate whether 
fully active enzyme was formed in the 
reconstitution reaction. Such a comparison 
indicated that the holoenzyme generated 
from freshly prepared pure apo-DSD was 
77% active, whereas holoenzyme gen- 
erated from the stored crude apoenzyme 
was only 19% as active as pure holenzyme. 
It is unlikely that the low activity observed 
for reconstituted crude apoenzyme was 
’ The product of the slope of each plot in Fig. 1 and the 
M, of pyridoxal-P yields this quantity. 
0.2 0.4 0.6 0.8 I.0 
Added Pyridoxal-P(ng) 
FIG. 1 Dependence of enzymic activity on the 
amount of added pyridoxal-P in the assay cuvette. 
Known amounts of pyridoxal-P were incubated with 
170 nM pure apo-DSD (0) and crude apo-DSD (13) 
at 37°C for I.5 min, whereupon 0.1 ml of the incubation 
mixture was transferred to a cuvette containing 1 ml 
0.5 M Hepps, pH 7.8, at 25°C. Assays were initiated 
after 15 min by the addition of 50 ~1 of a solution 
consisting of 5 mM NADH, 0.22 M D-SeIitIe, 350 units 
LDH/ml in 0.5 M Hepps, pH 7.8. The decrease in 
absorbance at 340 nm was followed on a recording 
spectrophotometer for at least 0.1 AU, and the rate of 
absorbance change equated to the plotted enzymic 
activities. 
caused by the presence of inhibitors, since 
the presence of crude apoenzyme did not 
alter the activity of pure holoenzyme. 
The possibility that the low activity gen- 
erated from crude apoenzyme was due to 
insufficient incubation time with pyridoxal-P 
was investigated in the studies presented in 
Fig. 2. Although the yield of regenerated 
activity is not at its maximal value at 15 
min, it is doubtful that the low yield of 
activity obtained with the stored crude 
apoenzyme can be attributed entirely to the 
15-min incubation time being too short. It is 
more likely, that the protein reconstituted 
from stored crude apoenzyme has a low 
catalytic activity. Storage of pure apo-DSD 
for several months also caused a lowering 
of the specific activity of the regenerated 
enzyme. As shown in Fig. 1, however, 
generation of reconstituted enzyme which 
is 100% active is not necessary to obtain 
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FIG. 2. Time dependence of the reconstitution of 
crude apo-DSD. Crude apo-DSD at 170 nM was in- 
cubated with 19 nM pyridoxal-P at 37°C. At the in- 
dicated times 0. l-ml samples of the incubation mixture 
were withdrawn and their enzymic activities deter- 
mined as described in the legend to Fig. 1. 
a linear relationship between enzymic activ- 
ity and the amount of pyridoxal-P. 
Figure 3 illustrates the effect on enzymic 
activity of incubating crude apo-DSD with a 
sample of deproteinized plasma plus known 
amounts of pyridoxal-P. The net activities 
plotted in Fig. 3 were obtained by sub- 
tracting from the activity observed with 
the sample, the activity arising from the 
small amount of unresolved holoenzyme 
present in apo-DSD. This activity was de- 
termined from separate assay of apo-DSD 
in the absence of plasma. Assay of pure 
holoenzyme in the presence of plasma 
indicated that the activity of holoenzyme 
is not altered significantly by the plasma 
which is present in the assay. This ob- 
servation supports the validity of the method 
used to correct the observed activity for the 
presence of holoenzyme in the apo-DSD. 
The two lines in Fig. 3 were obtained 
from the same sample of plasma. One hour 
prior to deproteinization pyridoxal-P (12.0 
&ml plasma) was added to the plasma 
sample that was used to obtain the data for 
the upper line in Fig. 3. The slope of the 
plots in Fig. 3 is equal to the proportionality 
constant (i.e., response factor) between the 
net activity and the amount of pyridoxal-P 
present. The amount of pyridoxal-P intro- 
duced in the assay cuvette by the sample 
is obtained by dividing the net activity 
observed for the sample in the absence of 
added pyridoxal-P (y-intercepts in Fig. 3) 
by the response factor for the assay. Division 
of these values by the volume of plasma 
(25.7 ~1 in these determination) in the 
assay cuvette should yield concentrations 
of pyridoxal-P in the plasma samples. The 
assays depicted in Fig. 3 indicate that 
the plasma sample to which no pyridoxal-P 
was added contained 14.0 ? 0.5 rig/ml 
pyridoxal-P and the plasma sample that was 






0.1 0.2 0.3 0.4 0.5 0.6 
Added Pyridoxal-P(ng) 
FIG. 3. Dependence of activity on added pyridoxal-P 
in the assay cuvette in the presence of a plasma sample 
(25.7 ~1). The net activities plotted are differences 
between observed activities and the activity arising 
from the unresolved holoenzyme present in the apo- 
DSD. The activity of unresolved holoenzyme (0.94 
x 10ms AU/min) was determined by assaying an in- 
cubation mixture wherein 0.5 M Hepps, pH 7.8, was 
added in place of the plasma sample. Samples were 
incubated with apoenzyme and assayed as described 
in the legend to Fig. 1. The assay cuvettes contained 
the indicated amounts of added pyridoxal-P plus a 
plasma sample corresponding to 25.7 ~1 of undiluted 
plasma (0). The open squares illustrate the effect of 
enriching the plasma sample with pyridoxal-P (12.9 
rig/ml) 1 h prior to deproteinization. 
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deproteinization contained 29.0 1?: 1.1 rig/ml 
pyridoxal-P. The difference between these 
two values corresponds to a 116 + 9% 
recovery of the added pyridoxal-P. Plasma 
enriched with pyridoxal-P and allowed to 
stand at room temperature for 24 h prior to 
deproteinization showed a 111% recovery 
of the added pyridoxal-P. The 24-h incuba- 
tion of pyridoxal-P with plasma should 
have been sufficient time for the added 
pyridoxal-P to bind plasma proteins. The 
good recovery (after both 1 and 24 h) 
of the added pyridoxal-P is consistent 
with the conclusion that all protein bound 
pyridoxal-P is released during the treat- 
ment with perchloric acid. These results 
contrast somewhat with those of Srivastava 
and Beutler (27), who observed a 70% 
recovery of added pyridoxal-P after it had 
incubated with plasma for 20 min-24 h. 
Perhaps the difference in recovery of added 
pyridoxal-P is due to differences in the 
methods used to deproteinize the plasma 
sample. 
It should be noted that the dependence 
of the observed activity on the amount of 
added pyridoxal-P is a function of the 
volume of plasma present in the incubation 
mixture, so that the efficiency of the 
reconstitution reaction decreases with in- 
creasing amounts of plasma. This reduction 
in efficiency may be caused by lowered 
affinity of apo-DSD for pyridoxal-P in 
the presence of a component of depro- 
teinized plasma such as chloride ion.8 The 
dependence of the response of the assay to 
added pyridoxal-P should be taken into 
account in designing modi~cations of the 
assay procedure. Either the same volume 
of plasma should be used in each set of 
8 In a separate study wherein trichloroacetic acid 
was used for deproteinization, reconstitution of the 
apoenzyme was observed to be markedly inhibited by 
trichloroacetate. The presence of this anion also re- 
sulted in a nonlinear time dependence of absorbance 
in the rate assay which made trichloracetic acid un- 
suitable for deproteinization in this assay. 
assays or the response of the assay to 
added pyridoxal-P should be determined for 
each assay wherein a different volume of 
plasma is used. Using this approach, the 
determined plasma pyridoxal-P concentra- 
tion was found to be independent of 
the volume of plasma used in the analysis. 
Although the response factor associated 
with the assay varies with the volume of 
plasma used, it does not appear to vary sig- 
nificantly among individuals. Plasma from 
a group of five volunteers exhibited re- 
sponse factors which were within 3% 
(standard deviation) of each other. Thus, 
the response factor and the activity asso- 
ciated with the unresolved holoenzyme in 
the apo-DSD need only be determined once 
each time a new solution of apo-DSD 
is prepared. The concentration (P) of 
pyridoxal-P in an individual sample of 
plasma can then be determined from the 
measured activity with a plasma sample 
using the relationship. 
P = (A -B)IRV, 
where A and B are the activities observed 
with the plasma sample and a blank con- 
taining no plasma, V is the volume of un- 
diluted plasma in the assay cuvette, and R 
is the response factor for the assay, which 
can be determined from the increase in 
activity produced by adding a known amount 
of pyridoxal-P to plasma, 
In addition to the convenience and 
rapidity of the pyridoxal-P assay reported 
in this work, only 0.4 ml of blood is re- 
quired to determine a plasma pyridoxal-P 
concentration. The present assay easily 
can be scaled down, however, so as to re- 
quire less than 0.1 ml of blood by using 
smaller cuvettes in the spectrophotometric 
assay. Furthermore, the reagents used in 
the assay are reasonably stable. The solu- 
tions containing the substrates and LDH 
can be stored at 4°C for at least 10 days 
with no detectable change in the response 
of the assay to added pyridoxal-P. Solutions 
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of crude apo-DSD could be stored for 4 11. Lumeng, L., Cleary, R. E., and Li, T. K. (1974) 
days at 4°C and used in the assay with Amer. J. Clin. Nutr. 27, 326-333. 
no change in the response of the assay to 
12. Tu, J. B., Blackwell, R. Q., and Lee, P. F. (1963) 
added pyridoxal-P.g 
J. Amer. Med. Assoc. 185, 83-86. 
13. Wachstein, M. J., Kellner, J. D., and Ortiz, J. M. 
(1960) Proc. Sot. Exp. Biol. Med. 103, 350- 
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